1Chen JH, Yeh WT, Chuang SY, Wu YY, Pan WH: Gender-specific risk factors for incident gout: a prospective cohort study. Clinical rheumatology 2012;31:239–245.
2Lytvyn Y, Perkins BA, Cherney DZ: Uric acid as a biomarker and a therapeutic target in diabetes. Canadian journal of diabetes 2015;39:239–246.
3Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH: Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis and rheumatism 2009;61:225–232.
4Wen CP, David Cheng TY, Chan HT, Tsai MK, Chung WS, Tsai SP, Wahlqvist ML, Yang YC, Wu SB, Chiang PH, Wen SF: Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. American journal of kidney diseases: the official journal of the National Kidney Foundation 2010;56:273–288.
5Kanbay M, Yilmaz MI, Sonmez A, Solak Y, Saglam M, Cakir E, Unal HU, Arslan E, Verim S, Madero M, Caglar K, Oguz Y, McFann K, Johnson RJ: Serum uric acid independently predicts cardiovascular events in advanced nephropathy. American journal of nephrology 2012;36:324–331.
6Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS: Uric acid and incident kidney disease in the community. Journal of the American Society of Nephrology: JASN 2008;19:1204–1211.
7Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R: Elevated uric acid increases the risk for kidney disease. Journal of the American Society of Nephrology: JASN 2008;19:2407–2413.
8Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M: Association of uric acid with change in kidney function in healthy normotensive individuals. American journal of kidney diseases: the official journal of the National Kidney Foundation 2010;56:264–272.
9Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V: Uric acid and long-term outcomes in CKD. American journal of kidney diseases: the official journal of the National Kidney Foundation 2009;53:796–803.
10Zhu P, Liu Y, Han L, Xu G, Ran JM: Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PloS one 2014;9:e100801.
11Jason P. Fine RJG: A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association 1997;94:496.
12Ceriello A, De Cosmo S, Rossi MC, Lucisano G, Genovese S, Pontremoli R, Fioretto P, Giorda C, Pacilli A, Viazzi F, Russo G, Nicolucci A, Group AM-AS: Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes, obesity & metabolism 2017;19:1570–1578.
13Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology C: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Annals of internal medicine 2006;145:247–254.
14Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, Committee S-TS, Investigators: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine 2013;369:1317–1326.
15Agarwal R: Defining end-stage renal disease in clinical trials: a framework for adjudication. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2016;31:864–867.
16Nagin DS: Group-based trajectory modeling: an overview. Annals of nutrition & metabolism 2014;65:205–210.
17Nagin DS, Tremblay RE: Analyzing developmental trajectories of distinct but related behaviors: a group-based method. Psychol Methods 2001;6:18–34.
18Nagin DS, Odgers CL: Group-based trajectory modeling in clinical research. Annual review of clinical psychology 2010;6:109–138.
19Lau B, Cole SR, Gange SJ: Competing risk regression models for epidemiologic data. American journal of epidemiology 2009;170:244–256.
20Fang J, Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. Jama 2000;283:2404–2410.
21Ndrepepa G: Uric acid and cardiovascular disease. Clinica chimica acta; international journal of clinical chemistry 2018;484:150–163.
22Murea M, Tucker BM: The physiology of uric acid and the impact of end-stage kidney disease and dialysis. Seminars in dialysis 2018
23Graham GG, Stocker SL, Kannangara DRW, Day RO: Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. Current rheumatology reports 2018;20:47.
24Richette P: [Gout: an overview of available urate lowering therapies]. Annales pharmaceutiques francaises 2012;70:133–138.
25Kim IY, Lee DW, Lee SB, Kwak IS: The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship. BioMed research international 2014;2014:638732.
26Roncal-Jimenez CA, Sato Y, Milagres T, Andres-Hernando A, Garcia GE, Bjornstad P, Butler-Dawson J, Sorensen C, Newman L, Krisher L, Madero M, Glaser J, Garcia-Trabannino R, Jarquin-Romero E, Song Z, Jensen T, Kuwabara M, Rodriguez-Iturbe B, Sanchez-Lozada LG, Lanaspa MA, Johnson RJ: Experimental Heat Stress Nephropathy and Liver Injury are Improved by Allopurinol. American journal of physiology Renal physiology 2018
27Gois PHF, Canale D, Volpini RA, Ferreira D, Veras MM, Andrade-Oliveira V, Camara NOS, Shimizu MHM, Seguro AC: Allopurinol attenuates rhabdomyolysis-associated acute kidney injury: Renal and muscular protection. Free radical biology & medicine 2016;101:176–189.
28Prieto-Moure B, Lloris-Carsi JM, Belda-Antoli M, Toledo-Pereyra LH, Cejalvo-Lapena D: Allopurinol Protective Effect of Renal Ischemia by Downregulating TNF-alpha, IL–1beta, and IL–6 Response. Journal of investigative surgery: the official journal of the Academy of Surgical Research 2017;30:143–151.
29Singh JA, Cleveland JD: Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Annals of the rheumatic diseases 2017;76:1669–1678.
30Kim S, Kim HJ, Ahn HS, Oh SW, Han KH, Um TH, Cho CR, Han SY: Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis. Kidney research and clinical practice 2017;36:274–281.
31Omori H, Kawada N, Inoue K, Ueda Y, Yamamoto R, Matsui I, Kaimori J, Takabatake Y, Moriyama T, Isaka Y, Rakugi H: Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clinical and experimental nephrology 2012;16:549–556.
32Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, Hata H, Shiono M: Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circulation journal: official journal of the Japanese Circulation Society 2013;77:2043–2049.
33Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, Hayashi Y, Asahi K, Terawaki H, Watanabe T: Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clinical and experimental nephrology 2015;19:1044–1053.
34Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R: Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. American journal of kidney diseases: the official journal of the National Kidney Foundation 2015;66:945–950.
35Wilson L, Saseen JJ: Gouty Arthritis: A Review of Acute Management and Prevention. Pharmacotherapy 2016;36:906–922.
36Yu KH, Chen DY, Chen JH, Chen SY, Chen SM, Cheng TT, Hsieh SC, Hsieh TY, Hsu PF, Kuo CF, Kuo MC, Lam HC, Lee IT, Liang TH, Lin HY, Lin SC, Tsai WP, Tsay GJ, Wei JC, Yang CH, Tsai WC: Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. International journal of rheumatic diseases 2018;21:772–787.